Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use

Author(s):  Teimouri Arezou, Yeung Pollen, Agu Remigius U

Issue:  Nov/Dec 2020 - Volume 24, Number 6
View All Articles in Issue

Page(s):  482-490

Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 1
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 2
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 3
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 4
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 5
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 6
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 7
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 8
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 9

Download in electronic PDF format for $75

Abstract:  Interest in the topical use of compounded diltiazem has increased. Published information on the stability of such products is scarce. The objective of this study was to investigate the stability of diltiazem hydrochloride compounded in cream (Glaxal Base), ointment (white petrolatum), and hydroxyethyl cellulose-based gel over 90 days at room (23°C), refrigerator (4°C), and elevated (40°C) temperatures, stored in white plastic and glass amber containers. Organoleptic properties, pH changes, and United States Pharmacopeia recommendations were used for assigning beyond-use-dates. The results showed that the currently recommended United States Pharmacopeia beyond-use date of 30 days is acceptable for diltiazem (2%) in Glaxal Base at 4°C and 23°C in either white plastic or glass amber jars. The cream, however, is not recommended for use if exposed to elevated temperatures (40°C) in white plastic jars but may be used within 7 days if stored in glass amber jars. A beyond-use date of 90 days for diltiazem (2%) hydroxyethyl cellulose-based gel, when maintained at 4°C or 23°C, in either white plastic or glass amber jars, is recommended. Gels exposed to elevated temperatures (40°C) should be used within14 and 30 days in glass amber and white plastic jars, respectively. Lastly, a BUD of 90 days for diltiazem (2%) ointment (white petrolatum) at 23°C stored in either jar type is acceptable. Ointment formulations exposed to elevated temperatures (40°C) may be used within 7 days in white plastic jars. Diltiazem (2%) in white petrolatum should not be stored at 4°C.

Related Keywords: diltiazem hydrochloride, topical preparations, calcium channel blocker, chronic anal fissures, diabetic ulcers, stability, storage conditions, commercial bases, temperature

Related Categories: DERMATOLOGY, DIABETES, EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Nov/Dec 2020
Pg. 482-490

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
May/Jun 2003
Pg. 170-174

Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Nov/Dec 2020
Pg. 501-508

Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Jul/Aug 2021
Pg. 344-351

Case Report: Wound Care of a Diabetic Foot Ulcer
Wynn Tom
Jul/Aug 2004
Pg. 265-267

Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 1
Riepl Mike
May/Jun 2020
Pg. 182-186

Case Report of Anal Fissures and Hemorrhoids Treated with Compounded Cromolyn Sodium and Naltrexone Hydrochloride in MEDISCA's SPG SUPPOSI-BASE
Earlywine Kerry
, Haiub Halema, Cull Erica, Lupatini Rodrigo, Sidhu Raman
Jan/Feb 2023
Pg. 6-10

Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
Nov/Dec 2018
Pg. 493

Basics of Compounding for Cold Sores or Fever Blisters
Allen Loyd V Jr
May/Jun 2004
Pg. 206-209

Diltiazem Hydrochloride 5-mg/mL Injection
Allen Loyd V Jr
May/Jun 2012
Pg. 241

Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications
Agbi Kelechi E
, Carvalho Maria, Phan Ha, Tuma Cristiane
Jan/Feb 2017
Pg. 22-27

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Riepl Mike
Nov/Dec 2022
Pg. 480-488

Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC
, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2016
Pg. 167-174

Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S
, Thyangarajapuram N
Sep/Oct 2003
Pg. 389-393

Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs
Gorman Gregory
, Sokom Simara, Coward Lori, Arnold John J
Mar/Apr 2017
Pg. 164-170

Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations
Bryson Evan
, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott
Mar/Apr 2015
Pg. 161-166

In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Kohan Hamed Gilzad
, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
Mar/Apr 2021
Pg. 146-155

A Compendium of Compounding Agents and Formulations, Part 4: Nifedipine and Pentoxifylline
Riepl Mike
Jul/Aug 2022
Pg. 270-274

Return to Top